Nesiritide (hBNP): A new class of therapeutic peptide for the treatment of decompensated congestive heart failure

Congestive Heart Failure

Volumn 7, Issue 2, 2001, Pages 78-87

  Katz, S D ^a  

^a Department of Orthopaedic Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; LOOP DIURETIC AGENT; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; RECEPTOR; SODIUM;

BRADYCARDIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE COST; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODYNAMICS; HUMAN; HYPOTENSION; NONHUMAN; REVIEW; SODIUM EXCRETION;

EID: 0034816765     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-5299.2001.00231.x     Document Type: Review

References (56)

1. Epidemiology of congestive heart failure
2. Heart failure in the 1990s: Evolution of a major public health problem in cardiovascular medicine
3. The treatment of heart failure
4. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Consensus recommendations for the management of chronic heart failure
5. Cardiac failure and sudden death in the Framingham study
6. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995
7. Characterization of the precipitants of hospitalization for heart failure decompensation
8. Outpatient management of severe congestive heart failure
9. Molecular biology of the natriuretic peptides and their receptors
10. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system."
11. Physiological role of silent receptors of atrial natriuretic factor
12. NO and cardiac diastolic function
13. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide
14. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure
15. Decreased atrial natriuretic peptide binding in renal medulla in rats with chronic heart failure
16. Atrial natriuretic factor: Pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure
17. Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure
18. Atrial natriuretic peptide in congestive heart failure in the dog: Plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects
19. Decreased density of binding sites for atrial natriuretic peptide on platelets of patients with severe congestive heart failure
20. Atrial natriuretic factor in normal subjects and heart failure patients
21. Hemodynamic and renal effects of atrial natriuretic peptide in congestive heart failure
22. Haemodynamic effects of atrial peptide infusion in heart failure
23. Hemodynamic, renal, and hormonal responses to alpha-human atrial natriuretic peptide in patients with congestive heart failure
24. Hemodynamic, renal and endocrine effects of atrial natriuretic peptide infusion in severe heart failure
25. A new natriuretic peptide in porcine brain
26. Atrial natriuretic peptide and its potential role in pharmacotherapy
27. Dual natriuretic peptide system in experimental heart failure
28. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure
29. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: A double-blind, placebo-controlled, randomized crossover trial
30. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
31. The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction
32. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure
33. Renal effects of brain natriuretic peptide in patients with congestive heart failure
34. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial
35. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure
36. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort
37. Recognition and treatment of left ventricular diastolic dysfunction
38. Factors released from endocardium of the ferret and pig modulated myocardial contraction
39. Myocardial contractile response to nitric oxide and cGMP
40. Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs
41. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart
42. Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure
43. Four-hour infusions of synthetic atrial natriuretic peptide in normal volunteers
44. Sympathoinhibitory effects of atrial natriuretic factor in normal humans
45. The interaction between atrial natriuretic peptide and cardiac parasympathetic function
46. Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration
47. Pharmacokinetics and biological actions of subcutaneously administered human brain natriuretic peptide
48. Long-term treatment with desmopressin in children with primary monosymptomatic nocturnal enuresis: An open multicentre study
49. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure
50. A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: The U.S. ecadotril pilot safety study
51. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure: The International Ecadotril Multi-centre Dose-ranging Study Investigators
52. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and furosemide in the treatment of patients with chronic heart failure
53. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition
54. Vasopeptidase inhibition: A new concept in blood pressure management
55. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
56. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure